Lilly receives EU approval for Taltz in psoriatic arthritis

Lilly has announced that its IL-17 inhibitor therapy Taltz has been approved in Europe for the treatment of psoriatic arthritis.

The European Commission has granted marketing authorisation for Taltz, alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients who cannot benefit from disease-modifying anti-rheumatic drug therapies.

Taltz has demonstrated its clinical safety and efficacy in two randomised placebo-controlled phase III studies – SPIRIT-P1 and SPIRIT-P2 – which included 780 adult patients with active psoriatic arthritis.

This is the second approved indication for Taltz in the EU, having previously been ratified for the treatment of adult patients with moderate to severe plaque psoriasis in adults who are candidates for systemic therapy in April 2016.

Arash Tahbaz, senior medical director for Lilly in the UK and northern Europe, said: "Symptoms often begin around a decade after the onset of psoriasis, and can severely impact people's lives and ability to work. We are proud to be able to offer a new treatment option that addresses both the joint and skin symptoms of psoriatic arthritis."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.